

Title (en)
BIOSYNTHETIC GLYCOPROTEIN POPULATIONS

Title (de)
BIOSYNTHEISCHE GLYKOPROTEINPOPULATIONEN

Title (fr)
POPULATIONS DE GLYCOPROTÉINES BIOSYNTHÉTIQUES

Publication
EP 4136107 A4 20240508 (EN)

Application
EP 21788321 A 20210416

Priority

- US 202063011991 P 20200417
- US 202063011993 P 20200417
- US 202063011985 P 20200417
- US 202063011959 P 20200417
- US 202063011974 P 20200417
- US 202063030808 P 20200527
- US 202063030765 P 20200527
- US 202063030787 P 20200527
- US 202063030823 P 20200527
- US 202063030829 P 20200527
- US 202063058332 P 20200729
- US 202063058354 P 20200729
- US 202063058369 P 20200729
- US 202063058345 P 20200729
- US 202063058351 P 20200729
- US 202163142987 P 20210128
- US 202163142981 P 20210128
- US 202163142983 P 20210128
- US 202163142982 P 20210128
- US 202163142985 P 20210128
- US 2021027666 W 20210416

Abstract (en)
[origin: WO2021211956A1] A population of antibodies, wherein less than 80% of the oligosaccharides covalently attached to the population of the antibodies via N297 residues thereof comprise a core fucose residue; and wherein the population of the antibodies comprises an antibody which Fc region comprises K338A and T437R mutations, or K248E and T437R mutations.

IPC 8 full level
C07K 16/00 (2006.01); **C12N 9/10** (2006.01); **C12N 9/88** (2006.01)

CPC (source: EP IL KR US)
A61P 35/00 (2018.01 - KR); **A61P 37/02** (2018.01 - EP IL); **C07K 16/00** (2013.01 - EP KR); **C07K 16/28** (2013.01 - EP IL KR); **C07K 16/2809** (2013.01 - EP IL); **C07K 16/2833** (2013.01 - EP IL KR US); **C07K 16/2878** (2013.01 - EP IL KR US); **C07K 16/2896** (2013.01 - EP IL KR US); **C07K 16/3069** (2013.01 - EP IL KR US); **C07K 16/40** (2013.01 - EP IL); **C12N 9/1051** (2013.01 - EP IL KR); **C12N 9/88** (2013.01 - EP IL KR); **C12Y 204/01068** (2013.01 - EP IL KR); **C12Y 402/01047** (2013.01 - EP IL KR); **A61K 2039/505** (2013.01 - KR); **C07K 2317/14** (2013.01 - EP IL); **C07K 2317/21** (2013.01 - EP); **C07K 2317/24** (2013.01 - EP IL); **C07K 2317/30** (2013.01 - KR); **C07K 2317/31** (2013.01 - EP IL US); **C07K 2317/34** (2013.01 - EP IL); **C07K 2317/41** (2013.01 - EP IL KR); **C07K 2317/52** (2013.01 - EP IL); **C07K 2317/524** (2013.01 - EP IL); **C07K 2317/526** (2013.01 - EP IL); **C07K 2317/71** (2013.01 - US); **C07K 2317/72** (2013.01 - EP); **C07K 2317/732** (2013.01 - EP IL KR US); **C07K 2317/734** (2013.01 - EP IL KR US); **C07K 2317/92** (2013.01 - EP IL); **C07K 2317/94** (2013.01 - EP IL)

Citation (search report)

- [XYI] US 2018044427 A1 20180215 - ARMSTRONG ANTHONY [US], et al
- [XY] WO 2012010562 A1 20120126 - INTERNAT DRUG DEV BIOTECH [FR], et al
- [X] US 2018030111 A1 20180201 - MONNET CELINE [FR], et al
- [X] AKITO NATSUME ET AL: "Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 68, no. 10, 15 May 2008 (2008-05-15), pages 3863 - 3872, XP007913550, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-07-6297
- [X] BOEKHOUT ANNELIES H. ET AL: "Trastuzumab", THE ONCOLOGIST, vol. 16, no. 6, 31 May 2011 (2011-05-31), pages 800 - 810, XP093144633, ISSN: 1083-7159, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.2010-0035> DOI: 10.1634/theoncologist.2010-0035
- See also references of WO 2021211956A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2021211956 A1 20211021; AU 2021255704 A1 20221222; CA 3177604 A1 20211021; CN 115702164 A 20230214; EP 4136107 A1 20230222; EP 4136107 A4 20240508; IL 297286 A 20221201; JP 2023522027 A 20230526; KR 20230005234 A 20230109; TW 202204393 A 20220201; US 2022356266 A1 20221110; UY 39174 A 20211029

DOCDB simple family (application)
US 2021027666 W 20210416; AU 2021255704 A 20210416; CA 3177604 A 20210416; CN 202180043339 A 20210416; EP 21788321 A 20210416; IL 29728622 A 20221013; JP 2022562640 A 20210416; KR 20227040282 A 20210416; TW 110113747 A 20210416; US 202117233021 A 20210416; UY 39174 A 20210416